Reunion Technology Digest
SEE OTHER BRANDS

Catch up with science and technology news from Reunion

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Monday, November 10th, 2025
Time: 9:00AM ET

Stifel 2025 Healthcare Conference
Date: Tuesday, November 11th, 2025
Time: 4:40PM ET

Jefferies Global Healthcare Conference
Date: Tuesday, November 18th, 2025
Time: 2:00PM GMT

A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com 


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions